U.S. Markets open in 2 hrs 37 mins
  • S&P Futures

    +4.25 (+0.11%)
  • Dow Futures

    +39.00 (+0.12%)
  • Nasdaq Futures

    -40.25 (-0.34%)
  • Russell 2000 Futures

    -3.40 (-0.19%)
  • Crude Oil

    +0.46 (+0.42%)
  • Gold

    +3.90 (+0.21%)
  • Silver

    -0.03 (-0.13%)

    -0.0026 (-0.2429%)
  • 10-Yr Bond

    -0.0680 (-2.38%)
  • Vix

    +0.08 (+0.27%)

    +0.0020 (+0.1587%)

    +0.0560 (+0.0438%)

    +388.50 (+1.33%)
  • CMC Crypto 200

    -23.03 (-3.42%)
  • FTSE 100

    +87.24 (+1.19%)
  • Nikkei 225

    +336.19 (+1.27%)

Danaher (DHR) Q3 Earnings Beat, Rise Y/Y on Sales Growth

  • Oops!
    Something went wrong.
    Please try again later.
·6 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Danaher Corporation DHR has reported better-than-expected results for the third quarter of 2020, with earnings surpassing estimates by 25.5%. Also, the company’s sales surpassed the consensus estimate by 6.6%.

The company’s adjusted earnings were $1.72 per share in the reported quarter, which outpaced the Zacks Consensus Estimate of $1.37. The bottom line increased 62.3% from the year-ago quarter’s figure of $1.06 mainly on sales growth and improved operating margin.

Revenue Details

In the quarter under review, the company’s net sales were $5,883.2 million, reflecting year-over-year growth of 34.5%. The results were driven by solid performance in Life Sciences and Diagnostics segments.

Organic sales in the quarter increased 9% and foreign-currency translations had a positive impact of 1%. Also, acquisitions/divestments boosted sales by 24.5%. As noted, Cytiva had a 5% positive contribution on sales growth in the quarter. Organic sales, including the impact of Cytiva, increased 14% year over year.

Also, the company’s top line surpassed the Zacks Consensus Estimate of $5,520 million.

On a geographical basis, its sales increased 39.5% year over year to $2,379 million in North America, while the same expanded 43.9% to $1,374 million in Western Europe. Also, sales in high-growth markets were $1,803.6 million, up 26.3% year over year, and that in other developed markets increased 12.4% to $326.2 million.

It reports net sales under three segments — Life Sciences, Diagnostics, and Environmental & Applied Solutions. The segmental information is briefly discussed below:

Revenues for the Life Sciences segment totaled $2,922.5 million, rising 72.5% year over year. Acquisitions/divestments had a positive contribution of 63% to sales growth, while foreign-currency translations boosted sales by 1%. Core sales grew 8.5% year over year.
However, Cytiva had a positive impact of 10% and including this, organic sales in the quarter increased 18.5% year over year.

Revenues in the Diagnostics segment grossed $1,889.1 million, increasing 18% year over year. The improvement came on the back of a 17.5% rise in core sales and a 0.5% gain from foreign-currency translations.

Revenues in the Environmental & Applied Solutions segment totaled $1,071.6 million, decreasing 1% year over year. The decline was due to a 1% fall in core sales.

Margin Profile

In the quarter under review, Danaher’s cost of sales increased 37.2% year over year to $2,657.7 million. It represented 45.2% of net sales compared with 44.2% in the year-ago quarter. Gross profit increased 32.1% year over year to $3,225.5 million, while margin decreased 100 basis points (bps) year over year to 54.8%.

Selling, general and administrative expenses of $1,795.3 million reflect a year-over-year increase of 29.9%. As a percentage of net sales, it represented 30.5% versus 31.6% in the year-ago quarter. Research and development expenses were $342.6 million, which rose 21.2% year over year. It represented 5.8% of net sales versus 6.5% in the year-ago quarter.

Operating income in the quarter under review increased 40% year over year to $1,087.6 million. Operating margin increased 80 bps to 18.5% in the quarter. Interest expenses in the quarter totaled $76.7 million, higher than $24 million reported in the year-ago quarter.

Balance Sheet and Cash Flow

Exiting the third quarter, Danaher had cash and cash equivalents of $5,687.7 million, up 2.7% from $5,539.3 million at the end of the last reported quarter. Long-term debt balance decreased 2.5% sequentially to $21,806.1 million.

During the first three quarters of 2020, the company raised $7,691.3 million through borrowings, with a maturity of more than 90 days. It also repaid $5,000 million borrowings, with a maturity of more than 90 days.

In the third quarter of 2020, the company generated net cash of $1,722.7 million from operating activities, reflecting a year-over-year increase of 93%. Capital used for purchasing property, plant and equipment totaled $187.3 million versus $162.1 million in the year-ago comparable period. Free cash flow (non-GAAP) in the quarter improved 110% year over year to $1,536 million.

The company paid out dividends worth $445.4 million to its shareholders in the first three quarters of 2020, reflecting an increase of 15.7% from the year-ago period.


In the quarters ahead, Danaher expects to benefit from a solid product portfolio, operational execution, dedicated workforce and a strong balance sheet.

For the fourth quarter of 2020, the company expects core revenues growth in high-single digits. In addition, it believes that Cytiva’s impact on core sales will be 300-400 bps and including this contribution, core sales growth in the quarter will be in low-double digits.

Danaher Corporation Price, Consensus and EPS Surprise


Danaher Corporation Price, Consensus and EPS Surprise
Danaher Corporation Price, Consensus and EPS Surprise

Danaher Corporation price-consensus-eps-surprise-chart | Danaher Corporation Quote

Zacks Rank & Other Stocks to Consider

With a market capitalization of $161.1 billion, Danaher currently carries a Zacks Rank #2 (Buy).

Three other top-ranked stocks in the industry are 3M Company MMM, Crane Co. CR and ITT Inc. ITT. All these stocks carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

In the past 60 days, earnings estimates for the two companies improved for the current year. Also, positive earnings surprise in the last reported quarter was 0.56% for 3M, 36.17% for Crane and 58.33% for ITT.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
3M Company (MMM) : Free Stock Analysis Report
ITT Inc. (ITT) : Free Stock Analysis Report
Danaher Corporation (DHR) : Free Stock Analysis Report
Crane Company (CR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research